Inhibition of Thymidylate Synthase by the Diastereoisomers of Leucovorin
Overview
Authors
Affiliations
The clinical formulation of leucovorin (5-CHO-FH4) is a mixture of diastereoisomers with markedly different pharmacologic properties. Comparatively little information is available concerning the cellular pharmacology of reduced folate stereoisomers, due largely to the difficulty in preparing sufficient quantities of these compounds for in vitro use. Recent improvements in HPLC technology have now facilitated this process, enabling studies of folate stereochemistry on a larger scale. Using purified (6R) and (6S) leucovorin, we examined the effects of these compounds on the enzymatic activity of Lactobacillus casei thymidylate synthase (TS) in a cell-free system. The natural (6S), unnatural (6R), and racemic (6R,S) leucovorin preparations inhibited TS activity by 50% at concentrations of 0.11, 2.1, and 0.52 mM, respectively. Dixon plots demonstrated the inhibition to be competitive, with Ki values of 85 microM, 1.59 mM, and 385 microM for (6S), (6R), and (6R,S) leucovorin, respectively. In view of the high doses of leucovorin given clinically and the slow clearance of the unnatural isomer, our observations suggest that leucovorin may have important direct inhibitory effects on folate-requiring enzymes.
Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment.
Franz C, Jotten L, Wuhrl M, Hartmann S, Klupp F, Schmidt T Cancer Rep (Hoboken). 2023; 6(12):e1899.
PMID: 37698257 PMC: 10728504. DOI: 10.1002/cnr2.1899.
Taflin H, Odin E, Derwinger K, Carlsson G, Gustavsson B, Wettergren Y Cancer Chemother Pharmacol. 2018; 82(6):987-997.
PMID: 30269276 PMC: 6267663. DOI: 10.1007/s00280-018-3690-9.
Meropol N, Petrelli N, Rustum Y, Rodriguez-Bigas M, Blumenson L, Frank C Invest New Drugs. 1995; 13(2):149-55.
PMID: 8617578 DOI: 10.1007/BF00872864.
Vokes E, OBrien S, Vogelzang N, Schilsky R, Ratain M Cancer Chemother Pharmacol. 1993; 32(5):347-52.
PMID: 8339384 DOI: 10.1007/BF00735917.
Mader R, Steger G, Rizovski B, Sieder A, Locker G, Gnant M Br J Clin Pharmacol. 1994; 37(3):243-8.
PMID: 8198932 PMC: 1364754. DOI: 10.1111/j.1365-2125.1994.tb04270.x.